Phase 2
Completed N=90
AGN-229666 for the Treatment of Allergic Conjunctivitis
Source: ClinicalTrials.gov NCT01754766 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Feb 2014
Primary outcomePrimary: Ocular Itching Score at Day 1 — 0.500; 0.319; 1.867 Score on a scale
Summary
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Ocular Itching Score at Day 1 |
0.500; 0.319; 1.867 | — |
| SECONDARY Ocular Itching Score at Day 15 |
0.358; 0.214; 1.258 | — |
| SECONDARY Conjunctival Hyperemia Score |
1.387; 1.345; 1.633 | — |
Eligibility Criteria
Inclusion Criteria
- Japanese patients living in Japan with a history of allergic conjunctivitis
- Willing to discontinue wearing contact lenses during the study period
Exclusion Criteria
- Use of nicotine products during the study period
- Presence of active eye infection (bacterial, viral, or fungal)
- History of an ocular herpetic infection
- Eye surgery intervention within 3 months and/or a history of refractive surgery within the past 6 months
Data sourced from ClinicalTrials.gov (NCT01754766). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.